Does Roche’s recent acquisition of Genentech mean the end of the big-biotech business model? Has Genentech lost it’s independence? Not so, if history decides to repeat itself. Roche has already bought (and sold) Genentech once before. It’s not unimaginable to think that they’re using the current economic crisis to do another value-based flip. Using an […]
I’ll be giving a talk at the Johns Hopkins Carey Business School Entrepreneurship Conference on March 21st titled “Entrepreneurship: What Not to Do.” The talk will cover cases in failed entrepreneurship in biotechnology, elucidating some of the forseeable and unforseeable factors which can lead to failure. Hope to see some readers there. If you can’t […]
The April 2009 issue of the Journal of Commercial Biotechnology is now available. This special issue on education was guest-edited by Arlen Meyers. The links below will take you to the abstract for each paper: Volume 15, Issue 2 Editorial PDF Arlen Meyers Articles Integrating virtual internships into online classrooms PDF Richard Conroy, Rana Khan […]
Courtesy of DrugPatentWatch.com: Drug Patent Expirations in March 2009 *Drugs may be covered by multiple patents
I am extending my “Best Practices in Biotechnology” book series with additional books in specific niches in biotechnology commercialization. This project is based on my observation that details on many of the critically important elements in biotechnology business development – including managing global operations and regulations, communication and public relations, financial management, and using marketing […]
I’ll be giving a talk at the Kogod School of Business on Tuesday February 24th on “Drug Development – Balancing National and Commercial Needs”. The basis of the talk is that countries need access to medicines, foreign currency, and tax revenues, while drug developers need profits (or else they will cease to exist). I’ll be […]
I will be opening the Business Matters for Scientists program at Johns Hopkins Carey School of Business on March 6th 2009. My focus will be providing an extensive overview of the biotechnology industry and insights on paths to entrepreneurship and business planning considerations. In addition to laying out the fundamentals for success, I will also […]
I will be opening the Business Matters for Scientists program at Johns Hopkins Carey School of Business on March 6th 2009. My focus will be providing an extensive overview of the biotechnology industry and insights on paths to entrepreneurship and business planning considerations. In addition to laying out the fundamentals for success, I will also […]
Courtesy of DrugPatentWatch.com: Drug Patent Expirations in February 2009 *Drugs may be covered by multiple patents
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Solving the FDA Crisis By John Avellanet, Managing Director and Principal of Cerulean Associates LLC News of the latest crisis under the FDA’s watch – salmonella contamination and the peanut plant in Georgia – has all the usual suspects calling for increased inspections […]
Get new actionable insights and updates from BiotechBlog
